Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $16.70 Consensus Price Target from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $16.60.

A number of research firms have commented on YMAB. Oppenheimer reduced their price target on Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 14th. Bank of America cut Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a report on Tuesday, April 22nd. HC Wainwright decreased their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Monday. Morgan Stanley lowered their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB opened at $4.17 on Thursday. The company has a 50 day simple moving average of $4.45 and a 200 day simple moving average of $6.93. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11. The firm has a market cap of $188.83 million, a PE ratio of -7.72 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.10. The firm had revenue of $20.90 million during the quarter, compared to analysts’ expectations of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. As a group, research analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.50% of the stock is currently owned by company insiders.

Institutional Trading of Y-mAbs Therapeutics

Several hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group lifted its stake in shares of Y-mAbs Therapeutics by 4,563.8% in the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company’s stock valued at $26,000 after buying an additional 5,796 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics in the 4th quarter valued at about $46,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Y-mAbs Therapeutics during the 1st quarter valued at about $49,000. Corton Capital Inc. acquired a new position in Y-mAbs Therapeutics during the 1st quarter valued at about $55,000. Finally, EntryPoint Capital LLC bought a new stake in Y-mAbs Therapeutics during the 1st quarter worth approximately $56,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.